1 February 2021 - A freeze by the new Biden administration on Trump era regulations will hit at least two rules aimed at lowering drug prices, including one dealing with insulin and EpiPens for under-served patients.
The halt follows a memo last month from White House chief of staff Ron Klain directing agencies to halt new and pending regulations from going into effect to ensure Biden officials have the opportunity to review them.